vs
Side-by-side financial comparison of ASHFORD HOSPITALITY TRUST INC (AHT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
ASHFORD HOSPITALITY TRUST INC is the larger business by last-quarter revenue ($259.0M vs $177.4M, roughly 1.5× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -26.8%, a 28.4% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -6.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -7.7%).
Ashford Hospitality Trust Inc is a U.S.-headquartered real estate investment trust focused on upper-upscale full-service hotel properties across key U.S. urban, suburban and resort markets. Its portfolio holds assets under top global hospitality brands, serving business and leisure travelers, with a focus on long-term value growth and stable shareholder returns.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AHT vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $259.0M | $177.4M |
| Net Profit | $-69.3M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -2.6% | 3.9% |
| Net Margin | -26.8% | 1.6% |
| Revenue YoY | -6.0% | 5.0% |
| Net Profit YoY | 44.2% | — |
| EPS (diluted) | $-12.85 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $259.0M | $196.9M | ||
| Q3 25 | $266.1M | $179.5M | ||
| Q2 25 | $302.0M | $181.1M | ||
| Q1 25 | $277.4M | $168.9M | ||
| Q4 24 | $275.5M | $187.3M | ||
| Q3 24 | $276.6M | $168.6M | ||
| Q2 24 | $316.5M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-69.3M | — | ||
| Q3 25 | $-60.1M | $5.4M | ||
| Q2 25 | $-30.4M | $-4.8M | ||
| Q1 25 | $-20.0M | $4.8M | ||
| Q4 24 | $-124.2M | — | ||
| Q3 24 | $-57.9M | $-143.5M | ||
| Q2 24 | $50.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -2.6% | 1.2% | ||
| Q3 25 | 4.6% | 3.5% | ||
| Q2 25 | 16.3% | 4.7% | ||
| Q1 25 | 22.2% | 1.2% | ||
| Q4 24 | -17.8% | 13.2% | ||
| Q3 24 | 7.3% | -82.8% | ||
| Q2 24 | 42.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -26.8% | — | ||
| Q3 25 | -22.6% | 3.0% | ||
| Q2 25 | -10.1% | -2.7% | ||
| Q1 25 | -7.2% | 2.8% | ||
| Q4 24 | -45.1% | — | ||
| Q3 24 | -20.9% | -85.1% | ||
| Q2 24 | 15.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-12.85 | $0.05 | ||
| Q3 25 | $-11.35 | $0.12 | ||
| Q2 25 | $-6.88 | $-0.11 | ||
| Q1 25 | $-4.91 | $0.10 | ||
| Q4 24 | $-13.64 | $0.38 | ||
| Q3 24 | $-12.39 | $-3.11 | ||
| Q2 24 | $2.50 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.1M | $144.3M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $-626.4M | $653.9M |
| Total Assets | $2.8B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $66.1M | $238.4M | ||
| Q3 25 | $81.9M | $246.3M | ||
| Q2 25 | $100.0M | $445.9M | ||
| Q1 25 | $85.8M | $493.6M | ||
| Q4 24 | $112.9M | $484.6M | ||
| Q3 24 | $119.7M | $453.8M | ||
| Q2 24 | $121.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $372.2M | ||
| Q3 25 | $2.6B | $376.7M | ||
| Q2 25 | $2.6B | $580.5M | ||
| Q1 25 | $2.7B | $583.4M | ||
| Q4 24 | $2.6B | $585.3M | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.8B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $-626.4M | $693.1M | ||
| Q3 25 | $-548.7M | $727.2M | ||
| Q2 25 | $-485.5M | $757.8M | ||
| Q1 25 | $-446.1M | $798.5M | ||
| Q4 24 | $-419.2M | $778.3M | ||
| Q3 24 | $-288.4M | $749.6M | ||
| Q2 24 | $-225.9M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.8B | $1.3B | ||
| Q3 25 | $3.0B | $1.3B | ||
| Q2 25 | $3.1B | $1.5B | ||
| Q1 25 | $3.1B | $1.6B | ||
| Q4 24 | $3.2B | $1.6B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $3.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | — |
| Free Cash FlowOCF − Capex | $-86.8M | — |
| FCF MarginFCF / Revenue | -33.5% | — |
| Capex IntensityCapex / Revenue | 27.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-135.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-15.7M | $43.7M | ||
| Q3 25 | $5.5M | $60.8M | ||
| Q2 25 | $16.3M | $12.0M | ||
| Q1 25 | $-25.0M | $35.5M | ||
| Q4 24 | $-23.6M | $33.1M | ||
| Q3 24 | $795.0K | $53.9M | ||
| Q2 24 | $8.0M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-86.8M | $43.5M | ||
| Q3 25 | $-226.0K | $57.0M | ||
| Q2 25 | $-3.6M | $9.3M | ||
| Q1 25 | $-44.8M | $26.9M | ||
| Q4 24 | $-131.6M | $31.0M | ||
| Q3 24 | $-21.8M | $49.8M | ||
| Q2 24 | $-22.9M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -33.5% | 22.1% | ||
| Q3 25 | -0.1% | 31.7% | ||
| Q2 25 | -1.2% | 5.1% | ||
| Q1 25 | -16.2% | 15.9% | ||
| Q4 24 | -47.8% | 16.6% | ||
| Q3 24 | -7.9% | 29.6% | ||
| Q2 24 | -7.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 27.5% | 0.1% | ||
| Q3 25 | 2.1% | 2.2% | ||
| Q2 25 | 6.6% | 1.5% | ||
| Q1 25 | 7.2% | 5.1% | ||
| Q4 24 | 39.2% | 1.1% | ||
| Q3 24 | 8.2% | 2.4% | ||
| Q2 24 | 9.8% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.16× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AHT
| Occupancy | $190.2M | 73% |
| Food And Beverage | $51.8M | 20% |
| Hotel Other | $16.6M | 6% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
